Of note, this trial employed an individualized titration schedule on a variety of background regimens, which is likely more applicable to typical clinical practice
Major areas of exploration include: Heart health
The 'Switch' is On: Proving the Viability of Oral Maintenance Therapy The ATTAIN-MAINTAIN study was a first-of-its-kind Phase 3 trial designed to answer a critical clinical question: can patients who have successfully lost weight on injectable GLP-1s (Wegovy or Zepbound) switch directly to an oral agent and maintain their results
Similarly, rates of stroke [110, 111], and new diagnoses and progression of cognitive impairment [168] are reduced in post hoc analyses of secondary endpoints in CVOTs of GLP-1RA in people with type 2 diabetes
What to Expect in Your Labs Triglyceride reductions on GLP-1 medications tend to appear relatively early compared to other metabolic improvements, often within the first two to three months of treatment as weight loss begins and dietary patterns shift
Theres no tapering-off regimen either, but thats true about many other medications, he notes